Tracers Available

CIRC is a National Research Platform that supports and facilitates nuclear imaging research in Singapore. Parties interested in the GMP compliant manufacture of novel or established radiopharmaceuticals can contact CIRC directly at circenquiries@nus.edu.sg

Product List

Application	Radionuclide	Radiopharmaceutical / Tracer	Use
Diagnostic	¹¹C	[¹¹C]Acetate	Traces oxidative metabolism as an alternative substrate to glucose; useful in oncology and cardiology, including assessment of myocardial oxygen consumption.
		[¹¹C]MTO (Metomidate)	Selectively binds adrenal cortex enzymes; supports characterisation and lateralisation of adrenal lesions in primary hyperaldosteronism.
		[¹¹C]MSTAT (Martinostat)	HDAC inhibitor analogue enabling in vivo imaging of histone deacetylase activity in cardiac disease, oncology and neurodegenerative or psychiatric disorders.

Diagnostic	¹⁸F	[¹⁸F]NAV-4694 (Flutafuranol)	High-affinity amyloid-ß tracer for sensitive detection of cerebral amyloid deposition in Alzheimer’s disease research and clinical evaluation)
		[¹⁸F]MK-6240 (Florquinitau)	Next-generation tau tracer targeting neurofibrillary tangles for detailed mapping of tau pathology in Alzheimer’s disease.
		[¹⁸F]FEPPA	TSPO ligand for imaging microglial and macrophage activation in neuroinflammation, systemic inflammatory conditions and selected oncology applications.

Diagnostic	⁶⁸Ga	[⁶⁸Ga]Ga-PSMA-11	Targets PSMA for sensitive detection, staging and recurrence assessment of prostate cancer and for selecting patients for PSMA-directed therapy.
		[⁶⁸Ga]Ga-NOTA-EB	Evans Blue derivative for visualising blood volume, vascular permeability and lymphatic drainage.
		[⁶⁸Ga]Ga-FAPI-46	Binds fibroblast activation protein, enabling imaging of tumour stroma and cancer-associated fibroblasts across a broad range of malignancies.
		[⁶⁸Ga]Ga-LNC1007	Dual-target heterodimer binding both FAP and integrin αvβ3 to characterise tumour cells and their microenvironment simultaneously.
		[⁶⁸Ga]Ga-DOTA-TATE	Somatostatin receptor subtype 2 tracer for imaging neuroendocrine tumours.
		[⁶⁸Ga]Ga-CPCR4 (PentixaFor)	CXCR4-targeting tracer for visualisation of chemokine receptor expression in oncology, inflammation and immune-related diseases.

Therapy	¹⁷⁷Lu	[¹⁷⁷Lu]Lu-LNC1003	PSMA-targeting radiotherapeutic (Evans Blue modified) for treatment of PSMA-expressing prostate cancer.
		[¹⁷⁷Lu]Lu-LNC1004	FAP-directed therapeutic agent designed for tumours with high fibroblast activation protein expression.
		[¹⁷⁷Lu]Lu-LNC1010	Somatostatin receptor 2–targeted radioligand for therapy of SSTR2-expressing tumours.
		[¹⁷⁷Lu]Lu-LNC1011	PSMA-targeting radiotherapeutic under investigation for metastatic castration-resistant prostate cancer.
		[¹⁷⁷Lu]Lu-DOTA EB-TATE	Evans Blue–modified SSTR2 radiotherapeutic for enhanced retention and treatment of neuroendocrine tumours.

Therapy	²²⁵Ac	[²²⁵Ac]Ac-LNC1011	Alpha-emitting PSMA radiotherapeutic candidate for resistant or advanced PSMA-positive prostate cancer.